According to a new study on a mouse model, blocking the activity of a protein known as SARM1 may be a useful strategy in Charcot-Marie-Tooth disease type 2A (CMT2A). A group of St. Louis researchers argue that such a strategy can prevent nerve loss and other neurodegenerative disorders.
“Our latest research suggests that […] we may be able to interfere with SARM1 ‘s ability to trigger harmful neuroinflammation” said Jeffrey Milbrandt, MD, PhD, one of the study’s senior authors and a professor at Washington University School of Medicine, Missouri, in its press release.
“We desperately need treatments for neurodegenerative diseases ,” Milbrandt said. “ With evidence of the central role of SARM1 in these diseases, we are very interested in finding ways to block this molecule – either with small molecule inhibitors or gene therapy techniques .”
We thank the Charcot Marie Tooth News online magazine for highlighting this important news (click on the link to read the whole article) and one of our patients for reporting it to us.
*is a critical mediator of a molecular pathway leading to programmed axon destruction.